Temporary Stool-Diverting device aims to prevent dangerous leaks after colon surgery

NCT ID NCT03423485

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests a temporary device called CG-100 that is placed inside the bowel after colorectal surgery to divert stool away from the surgical connection (anastomosis). The goal is to see if the device can create a leak-proof seal and reduce the risk of anastomotic leakage, a serious complication. About 30 adults scheduled for elective colorectal surgery will receive the device during their operation and be followed for about 10 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CG-100 Intraluminal Bypass Device
What this could lead to
If successful, this device could reduce the risk of dangerous leaks at the surgical connection after colorectal surgery, potentially improving recovery and reducing complications.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to all patients. The device may fail to seal properly or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jan 2018

Finished

Dec 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The patient is willing to comply with protocol-specified follow-up evaluations 2. Patient 22-75 years of age at screening 3. The patient is scheduled to undergo an elective colorectal surgery (open, laparoscopic, or robotic) which will require the creation of an anastomosis, maximally 20 cm proximal from the anal verge 4. The patient or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB). Exclusion Criteria: Preoperative 1. Pregnant or nursing female subjects. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test. 2. Patient surgical treatment is acute (not elective) 3. Patient has local or systemic infection at the time of intervention (e.g., peritonitis) 4. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study 5. Patients with ASA classification \> 3 6. Albumin \< 30 g/liter 7. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease 8. BMI ≥ 40 9. Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery. 10. Patient is participating in another clinical trial within 30 days of screening 11. Patient has been taking regular steroid medication in the last 6 months. 12. Patient has contraindications to general anesthesia 13. Patient has preexisting sphincter problems 14. Patient has evidence of extensive local disease in the pelvis 15. Any condition which in the opinion of the investigator may jeopardize the patient's safe participation Intraoperative (prior to device deployment) 16. Anastomosis is located more than 20 cm from the anal verge 17. Internal diameter lumen of the colon is smaller than 25 mm or larger than 34 mm 18. Blood loss (\> 500 cc) 19. Anastomosis was not performed for any reason other than consequences as a result of use of the study device -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal surgery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHUV, University Hospital Vaudois

    Lausanne, Switzerland

  • Carmel Medical Center

    Haifa, Israel

  • Hospital Beaujon

    Paris, Clichy, 92110, France

  • Soroka Medical Center

    Beersheba, 85025, Israel

  • University Hospital of Hamburg

    Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.